Clinical Study Of The Xuanjuzhenwan To The Deficiency Of Liver And Kidney Ankylosing Spondylitis In Remission Stage Patients

Purpose:Clinical study of the Xuanjuzhenwan to the deficiency of liver and kidney Ankylosing Spondylitis in Remission Stage patients’clinical symptoms, signs and the change of serology, to evaluate the clinical efficacy and recurrence of the disease.Methods:To conform to the standard of the deficiency of liver and kidney Ankylosing Spondylitis in remission stage patients were randomly divided into a control group of 30 patients and treatment group of 30 patients.The control group with sulfasalazine enteric coated tablets in the treatment and the treatment group with sulfasalazine enteric coated tablets plus the Xuanjuzhenwan in the treatment. In order to evaluate The Xuanjuzhenwan effects with Ankylosing Spondylitis in remission stage patients,we observation the patients’clinical symptoms, signs and the change of serology in 12 weeks and 24 weeks,and compare efficacy and relapse of the Traditional Chinese and the Western Medicine.Results:In this study, after 12 weeks the Traditional Chinese Medicine efficacy evaluation of the control group total effective rate was 6.67% and the treatment group total effective rate was 26.67%. The treatment group was better than the control group. After 24 weeks the Traditional Chinese Medicine efficacy evaluation of the control group total effective rate was 17.24% and the treatment group total effective rate was 46.67%. The treatment group was better than the control group.The Western medicine curative effecy evaluation of ASAS20% after 12 weeks of the control group total effective rate was 10.00%.And the treatment group total effective rate was 23.33%,which was better than the control group.After 24 weeks the Western medicine efficacy evaluation of ASAS20% of the control group total effective rate was 67.07%.And the treatment group total effective rate was 76.67%,which was better than the control group.After 12 weeks the control group recurrence rate was 3.33%.After 24 weeks the control group recurrence rate was 17.24%.The treatment group has been to maintain remission, recurrence rate was 0.00%. The Xuanjuzhenwan combined sulfasalazine enteric coated tablets can be controlled in a stable condition.Conclusion:The Xuanjuzhenwan combined sulfasalazine enteric coated tablets can improve the patients’ symptoms, signs and laboratory indicators in Ankylosing Spondylitis remission stage. The Xuanjuzhenwan combined sulfasalazine enteric coated tablets can reduce the recurrence of the disease.